PDCD1 and hepatocellular carcinoma: Subsequently, a number of clinical trials on ICIs monotherapy for advanced HCC have found that PD-1/PD-L1 mAb was well tolerated, and the ORR in advanced HCC could reach to 10.0%-20.0% (34, 36, 38, 39).